Form 4: ALX Oncology CEO Granted 912,000 Stock Options

ALX Oncology Holdings Inc. CEO Jason Lettmann was granted 912,000 stock options with an exercise price of $1.48, vesting over 48 months.

Summary

• Jason Lettmann, Chief Executive Officer and Director of ALX Oncology Holdings Inc. (ALXO), was granted 912,000 stock options.
• The stock options have an exercise price of $1.48 per share.
• The transaction date for this grant was January 26, 2026.
• The options will vest in 48 equal monthly installments, commencing on February 26, 2026.
• The expiration date for these stock options is January 25, 2036.
• Following this transaction, Jason Lettmann beneficially owns 912,000 derivative securities directly.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. The grant of stock options to the CEO aligns management's long-term interests with shareholder value, a standard practice in executive compensation. It does not reflect operational performance or financial results.

Positives

• The grant of stock options to the Chief Executive Officer aligns management's long-term financial interests with those of the shareholders, incentivizing performance and value creation.
• The options have a 10-year expiration period, providing a substantial window for potential value realization.

Negatives

• No immediate negatives are apparent from this routine compensation disclosure.

Risks

• Potential future dilution for existing shareholders if the options are exercised, increasing the total number of outstanding shares.
• The value of the options is dependent on the future market price of ALX Oncology Holdings Inc. common stock, which is subject to market volatility and company performance.

Future Outlook

The filing details a future vesting schedule for the granted stock options, indicating a long-term incentive structure for the CEO. No other forward-looking statements or guidance are provided.

Industry Context

The grant of stock options is a common form of executive compensation in the biotechnology and pharmaceutical industries, designed to attract, retain, and incentivize key leadership by linking their financial success to the company's long-term performance and shareholder value.

Comparison to Industry Standards

• The structure of this option grant, including the vesting schedule and expiration term, is consistent with typical executive equity compensation packages observed across the biotechnology sector. Companies like Amgen, Gilead Sciences, and Regeneron frequently utilize similar long-term incentive plans for their executives to foster alignment with shareholder interests.

Related Party Transactions

• The transaction involves the grant of stock options from ALX Oncology Holdings Inc. to its Chief Executive Officer and Director, Jason Lettmann, as part of his compensation package.

Stakeholder Impact

• Shareholders: Potential for future dilution upon exercise of options, but also benefit from increased alignment of management's interests with long-term stock performance.
• Employees (CEO): Direct impact on the CEO's long-term compensation and wealth accumulation, contingent on company performance.

Next Steps

• The stock options will begin vesting in 48 equal monthly installments starting February 26, 2026.

Key Dates

Keywords

ALX Oncology, ALXO, Stock Option, CEO, Jason Lettmann, Insider Transaction, Form 4, Equity Grant, Executive Compensation, Oncology, Biotechnology